Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS:  Peter Read More

2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

2024-03-25T09:16:48-07:00October 21st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. AUTHORS: Peter Read More

2024-03-25T09:19:31-07:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. AUTHORS: Paul Read More

2024-03-25T09:21:21-07:00May 1st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

PUBLICATION: Med Oncol. (2014) 31: 163. AUTHORS: Soley Bayraktar, Read More

2024-03-25T10:18:35-07:00September 4th, 2014|BluePrint, Evidence, Neoadjuvant|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION:  Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS:  Read More

2024-03-25T10:46:58-07:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|
Go to Top